Drug intelligence / Profile preview

dKIF976

Development stage: Unknown
Lead developer: Accutar Biotechnology
Modality: Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

dKIF976 is a first-in-class KIF11 degrader antibody-drug conjugate (DAC) developed using Accutar's chimeric degrader platform. It achieves specific and potent degradation of the mitotic kinesin KIF11, leading to mitotic arrest and robust inhibition of cancer cell growth. The drug is designed as a targeted therapy for cancer, leveraging the mechanism of targeted protein degradation to eliminate KIF11 in tumor cells[1][3].

Targets

KIF11 (Kinesin Spindle Protein)

Beyond the preview

Go deeper on dKIF976.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dKIF976.

Explore the full profile